Table 3.

Impact of 150 mg Elagolix QD for 12 Months or 200 mg Elagolix BID for 3 Months on Median 10‐Year Risk of Hip Fracture and Major Osteoporotic Fracture: All Patients and by Percentile of Postmenopausal BMD (g/cm²) in the Absence of Elagolix Treatment

Age strata, years				Post‐menopausal BMD in the absence of elagolix treatment
	All patients			< 25th percentile			25th to 75th percentile			>75th percentile
	Not treated with elagolix	Treated with elagolix	Difference	Not treated with elagolix	Treated with elagolix	Difference	Not treated with elagolix	Treated with elagolix	Difference	Not treated with elagolix	Treated with elagolix	Difference
150 mg QD for 12 months
Median 10‐year risk of hip fracture, %
50–59	0.18	0.19	0.01	0.83	0.87	0.04	0.18	0.19	0.01	0.02	0.02	0.00
60–69	0.49	0.51	0.02	1.87	1.95	0.09	0.48	0.50	0.02	0.10	0.10	0.00
70–79	2.14	2.22	0.08	7.03	7.31	0.28	2.09	2.18	0.09	0.41	0.42	0.01
Median 10‐year risk of major osteoporotic fracture, %
50–59	4.70	4.73	0.03	7.23	7.34	0.11	4.84	4.88	0.04	2.62	2.64	0.02
60–69	6.97	7.03	0.07	10.89	11.08	0.19	7.08	7.15	0.07	4.52	4.56	0.04
70–79	10.68	10.83	0.15	19.71	20.16	0.45	10.81	10.96	0.15	6.21	6.27	0.06
200 mg BID for 3 months
Median 10‐year risk of hip fracture, %
50–69	0.18	0.19	0.01	0.83	0.87	0.04	0.18	0.19	0.01	0.02	0.02	0.00
60–69	0.49	0.51	0.02	1.87	1.95	0.09	0.48	0.50	0.02	0.10	0.10	0.00
70–79	2.14	2.22	0.08	7.03	7.29	0.26	2.09	2.17	0.08	0.41	0.42	0.01
Median 10‐year risk of major osteoporotic fracture, %
50–69	4.70	4.73	0.02	7.23	7.33	0.10	4.84	4.88	0.04	2.62	2.64	0.02
60–69	6.97	7.03	0.06	10.89	11.07	0.18	7.08	7.15	0.06	4.52	4.56	0.04
70–79	10.68	10.82	0.14	19.71	20.14	0.43	10.81	10.95	0.14	6.21	6.27	0.06

BID = Twice daily; QD = once daily.